Biogen to buy experimental brain drug

Jan 25, 2018

Massachusetts-based Biogen announced it is buying Karyopharm’s experimental brain drug in a deal worth up to $217 million.

Biogen will pay $10 million upfront to Karyopharm for the XPO1 inhibitor KPT-350, with the remaining $207 million in future milestone payments dependent on clinical trial results. KPT-350 is a novel therapeutic candidate that works by inhibiting XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.

While the buy is a good fit for Biogen's pipeline, investors have been anticipating a much larger deal in order to ensure Biogen's continued growth.

Biogen announced the acquisition within its Q4 report.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments